Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir
Eric F. Donaldson, Patrick R. Harrington, Julian J. O'Rear, Lisa K. Naeger – 14 August 2014 – Sofosbuvir (Sovaldi, SOF) is a nucleotide analog prodrug that targets the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase and inhibits viral replication. High sustained virological response rates are achieved when SOF is used in combination with ribavirin with or without pegylated interferon in subjects with chronic HCV infection. Potential mechanisms of HCV resistance to SOF and other nucleos(t)ide analog NS5B polymerase inhibitors are not well understood.